Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide.
Solid track record with reasonable growth potential and pays a dividend.
Share Price & News
How has Eli Lilly's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LLY has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: LLY exceeded the Swiss Pharmaceuticals industry which returned 9.4% over the past year.
Return vs Market: LLY exceeded the Swiss Market which returned 3.4% over the past year.
Price Volatility Vs. Market
How volatile is Eli Lilly's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Eli Lilly undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LLY (CHF155) is trading below our estimate of fair value (CHF191.43)
Significantly Below Fair Value: LLY is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: LLY is poor value based on its PE Ratio (27.3x) compared to the XE Pharmaceuticals industry average (24.1x).
PE vs Market: LLY is poor value based on its PE Ratio (27.3x) compared to the Swiss market (19.3x).
Price to Earnings Growth Ratio
PEG Ratio: LLY is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: LLY is overvalued based on its PB Ratio (48.7x) compared to the CH Pharmaceuticals industry average (3.5x).
How is Eli Lilly forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LLY's forecast earnings growth (12.9% per year) is above the savings rate (-0.2%).
Earnings vs Market: LLY's earnings (12.9% per year) are forecast to grow faster than the Swiss market (8.1% per year).
High Growth Earnings: LLY's earnings are forecast to grow, but not significantly.
Revenue vs Market: LLY's revenue (6.5% per year) is forecast to grow faster than the Swiss market (2.6% per year).
High Growth Revenue: LLY's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LLY's Return on Equity is forecast to be very high in 3 years time (128.6%).
How has Eli Lilly performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LLY has high quality earnings.
Growing Profit Margin: LLY's current net profit margins (24%) are higher than last year (11.8%).
Past Earnings Growth Analysis
Earnings Trend: LLY's earnings have grown by 14.3% per year over the past 5 years.
Accelerating Growth: LLY's earnings growth over the past year (115.9%) exceeds its 5-year average (14.3% per year).
Earnings vs Industry: LLY earnings growth over the past year (115.9%) exceeded the Pharmaceuticals industry 7%.
Return on Equity
High ROE: Whilst LLY's Return on Equity (173.07%) is outstanding, this metric is skewed due to their high level of debt.
How is Eli Lilly's financial position?
Financial Position Analysis
Short Term Liabilities: LLY's short term assets ($14.0B) exceed its short term liabilities ($12.6B).
Long Term Liabilities: LLY's short term assets ($14.0B) do not cover its long term liabilities ($25.3B).
Debt to Equity History and Analysis
Debt Level: LLY's debt to equity ratio (531.9%) is considered high.
Reducing Debt: LLY's debt to equity ratio has increased from 55% to 531.9% over the past 5 years.
Debt Coverage: LLY's debt is well covered by operating cash flow (28.9%).
Interest Coverage: LLY's interest payments on its debt are well covered by EBIT (18.9x coverage).
What is Eli Lilly current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: LLY's dividend (1.79%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.92%).
High Dividend: LLY's dividend (1.79%) is low compared to the top 25% of dividend payers in the Swiss market (3.88%).
Stability and Growth of Payments
Stable Dividend: LLY's dividends per share have been stable in the past 10 years.
Growing Dividend: LLY's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (44.1%), LLY's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: LLY's dividends in 3 years are forecast to be well covered by earnings (40.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dave Ricks (52yo)
Mr. David A. Ricks, also known as Dave, served as a Director of Elanco Animal Health Incorporated until March 2019. He has been the Chief Executive Officer and President of Eli Lilly and Company since Janu ...
CEO Compensation Analysis
Compensation vs Market: Dave's total compensation ($USD21.28M) is above average for companies of similar size in the Swiss market ($USD6.69M).
Compensation vs Earnings: Dave's compensation has increased by more than 20% in the past year.
|Senior VP & CFO||2.5yrs||US$7.35m||0.0043% $6.0m|
|Senior VP||2.08yrs||US$6.66m||0.011% $15.0m|
|Chief Operating Officer of Loxo Oncology||no data||no data||no data|
|Chief Accounting Officer & VP of Finance||7.67yrs||no data||0.00071% $995.3k|
|Vice President of Finance & Special Projects||3.5yrs||no data||no data|
|Senior VP & Chief Information and Digital Officer||4yrs||no data||0.0023% $3.2m|
|Vice President of Investor Relations||no data||no data||no data|
|Senior VP of Enterprise Risk Management and Chief Ethics & Compliance Officer||7.5yrs||no data||0.0032% $4.6m|
|Senior VP & General Counsel||0.42yr||no data||no data|
|Senior Vice President of Corporate Affairs & Communications||3.08yrs||no data||0.00048% $672.9k|
|Vice President of Corporate Business Development||0.92yr||no data||no data|
Experienced Management: LLY's management team is considered experienced (3.3 years average tenure).
|Independent Director||12.42yrs||US$311.00k||no data|
|Independent Director||25.5yrs||US$302.67k||0.00039% $546.7k|
|Chairman Emeritus||11.5yrs||US$13.06m||no data|
|Independent Director||6.67yrs||US$357.00k||0.0050% $7.1m|
|Independent Director||14.67yrs||US$325.00k||0.000010% $14.0k|
|Independent Director||11.25yrs||US$306.00k||no data|
|Independent Director||8.08yrs||US$312.00k||no data|
|Lead Independent Director||1.17yrs||US$326.33k||no data|
|Independent Director||8.58yrs||US$306.00k||no data|
|Independent Director||3.75yrs||US$306.00k||no data|
|Independent Director||6.83yrs||US$294.00k||no data|
Experienced Board: LLY's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Eli Lilly and Company's company bio, employee growth, exchange listings and data sources
- Name: Eli Lilly and Company
- Ticker: LLY
- Exchange: SWX
- Founded: 1876
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$148.549b
- Listing Market Cap: US$140.184b
- Shares outstanding: 906.45m
- Website: https://www.lilly.com
Number of Employees
- Eli Lilly and Company
- Lilly Corporate Center
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LLY||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1969|
|LLY||SWX (SIX Swiss Exchange)||Yes||Common Stock||CH||CHF||Jan 1969|
|LLY *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1969|
|0Q1G||LSE (London Stock Exchange)||Yes||Common Stock||GB||CHF||Jan 1969|
|LLY||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1969|
|LLY||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Jan 1969|
|LLYZ||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Stock||GB||CHF||Jan 1969|
|LLY||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jan 1969|
|LLYC||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jan 1969|
|LILY34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH REPR 0.5 COM NPV||BR||BRL||Aug 2012|
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; AbCellera Biologics Inc.; and Sermonix Pharmaceuticals Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/15 21:26|
|End of Day Share Price||2020/07/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.